ICS insights - March 2025

Will we see you at LogiPharma 2025?

Join us at LogiPharma 2025, where ICS will be sharing a booth with Alloga . Together, as part of the Cencora family, we offer trusted third-party logistics (3PL) solutions that meet the unique demands of the pharmaceutical sector.

We look forward to seeing you there: Lyon, France, April 8 – 10. Booth 79.

Cryogenic storage and transportation for cell and gene therapies

Krystal Haynes , Senior Director of International 3PL Business Development, was featured in the latest episode of Running on Ice. Join Krystal as she goes deep into the fascinating world of cryogenic storage and transportation for cell and gene therapies.

Watch now

Cryogenic logistics: Meeting the demands of advanced therapies

The rise of cell and gene therapies (CGTs) has revolutionized the biopharmaceutical industry, bringing new treatments to patients with previously untreatable diseases. These innovative treatments, however, come with unique distribution challenges. Unlike traditional pharmaceuticals, CGTs often consist of delicate biological materials like living cells, genetically modified viruses, or engineered tissues. These therapeutics are highly sensitive to temperature fluctuations and require precise and extremely cold temperatures to remain viable throughout the supply chain. This has made cryogenic storage and distribution, involving the handling of materials at extremely low temperatures (below -150°C), essential to maintain the viability and efficacy of these life-saving therapies.

The need for precision in cryogenic logistics

To ensure their therapeutic potential, the integrity of complex CGTs must be maintained throughout the entire supply chain, from the manufacturing facility to the patient's bedside. Cryogenic storage and transportation play a critical role in ensuring the long-term stability of advanced therapies by safeguarding them from temperature-induced degradation and preserving their therapeutic efficacy. The maintenance of a cryogenic environment necessitates specialized infrastructure, equipment, and expertise, including:

• Specialized storage: Utilization of cryogenic storage tanks, freezers, and dewars engineered to uphold ultra-low temperatures with minimal temperature fluctuations
• Temperature monitoring and control systems: Implementation of sophisticated systems that continuously monitor and log temperature data, promptly detecting any deviations for immediate corrective actions.

Keep reading now

DCSCA stabilization period ends

As the 12-month stabilization period of the U.S. Drug Supply Chain Security Act (DCSCA) concluded in November 2024, legislation is now in full effect. Serialization still remains at the heart of this legislation, and we most now extract value beyond compliance.

Get our updated serialization white paper now

Comparator sourcing

Discover our comparator sourcing service. With global reach, tailored strategies, and unwavering commitment, we ensure efficient and secure access to necessary comparator drugs.

Explore now

Contact us today to see how we can support your third-party logistics needs and goals